Ataxia - Redenlab

Most people diagnosed with Friedreich ataxia are concerned about their communication, rating speech one of the most important features of the disease requiring treatment (Food and Drug Administration (FDA) Externally-led Patient-Focused Drug Development Meeting, 2017). Dysarthria and dysphonia are highly prevalent in hereditary ataxia, worsening with disease progression. Impairments impact all speech subsystems rendering speech slow, unclear and difficult to understand.

Redenlab’s speech tests are designed to enhance a sponsor’s ability to make decisions about the efficacy of their therapies. We use objective markers of speech to capture change in disease and communication, adding value to trial clinical endpoints.

Learn more about our products

Enhanced assessment for ataxia clinical trials

Decades of research experience

Redenlab’s data capture and analysis tools capitalize on decades of research and experience in analyzing speech, created by a dedicated clinical science team.

Designed for adults and children

We understand the difference of early monitoring and have designed our tools to be flexible and easy to use on individuals of all ages and abilities.

Key opinion leaders in the field

Redenlab scientists are leaders in communication assessment, with globally recognised expertise in hereditary ataxias. Their team continue to work consumers in specialist clinics for Friedreich ataxia and Ataxia Telangiectasia.

Extensive historical dataset

Redenlab has an extensive dataset of historical speech data in Friedreich ataxia and spinocerebellar ataxia that is available for comparison against your clinical trial data, enabling a more accurate comparison between treatment and control groups.

Purpose built algorithms

Speech and language phenotypes manifest in different ways based on underlying neuropathology. Redenlab draw from their existing datasets, theoretical and clinical knowledge of ataxia and statistical expertise to build algorithms specific to key components of communication.

Sensitive to pathology

Redenlab’s speech features have proven links to disease progression, underlying genetic profiles and associated domains like cognition.

Redenlab ataxia experience

Sites

40

Patients

500

Languages

14

Clinical trials

10+

Natural history studies

10+

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with A-T, a rare and complex neurodegenerative disease with no approved treatment.

International Congress for Ataxia Research 2024

Redenlab is excited to announce that Prof. Adam Vogel will be speaking at the upcoming International Congress for Ataxia Research...

The role of verbal fluency in the cerebellar cognitive affective syndrome scale in Friedreich Ataxia

Redenlab’s CEO, Adam Vogel, co-wrote "The Role of Verbal Fluency in the Cerebellar Cognitive Affective Syndrome Scale in Friedreich Ataxia"...

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with A-T, a rare and complex neurodegenerative disease with no approved treatment.

Rapid repetitive syllable sounds associate with episodic memory, executive function, and working memory in cognitively healthy and subjectively impaired older adults

Could a 10-second speech test repeating “pa,” “ta,” “ka” be the key to earlier detection of Alzheimer’s risk? Our new research suggests it might.

What can speech tell us about pain?

Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain, but also a tool to measure and even modulate it?